Page last updated: 2024-12-05

sulfamethazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfamethazine is a sulfonamide antibiotic used to treat bacterial infections in animals, particularly those affecting the respiratory and urinary tracts. It is synthesized through a multi-step process involving the reaction of p-aminobenzenesulfonamide with 4-methyl-2-aminopyrimidine. Sulfamethazine inhibits the synthesis of dihydrofolic acid, an essential coenzyme in bacterial metabolism, thereby preventing bacterial growth. Its importance lies in its effectiveness against a wide range of bacteria, including E. coli, Salmonella, and Pasteurella. It is studied to understand its pharmacokinetic properties, efficacy against emerging bacterial strains, and potential side effects. Research focuses on developing alternative treatments to minimize the risk of antibiotic resistance and improve animal welfare.'

Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5327
CHEMBL ID446
CHEBI ID102265
SCHEMBL ID151305
MeSH IDM0020748

Synonyms (298)

Synonym
BIDD:PXR0093
AC-16126
MLS001077331
BRD-K11640013-001-02-6
BRD-K11640013-236-03-6
nsc-683529
benzenesulfonamide, 4-amino-n-(4,6-dimethyl-2-pyrimidinyl)-
MLS000069711 ,
diazyl
KBIO1_000293
DIVK1C_000293
4,6-dimethyl-2-sulfanilamidopyrimidine
n(sup1)-(4,6-dimethyl-2-pyrimidyl)sulfanilamide
superseptyl
benzenesulfonamide,6-dimethyl-4-pyrimidinyl)-
sulfadimethylpyrimidine
sulfa-isodimerazine
vertolan
sulfodimezine
sulphadimethylpyrimidine
sulphodimezine
sulphamethasine
sulfadimesin
primazin
sulfodimesin
dimezathine
4-amino-n-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide
pirmazin
sulfadimesine
sulfamezathine
n(sup1)-(2,6-dimethylpyrimid-4-yl)sulfanilamide
cremomethazine
sulphamezathine
sulphamethazine
azolmetazin
superseptil
mermeth
sulphadimidine
dimidin-r
sulfadine
sulfadimezin
n-(4,6-dimethyl-2-pyrimidyl)sulfanilamide
sulfanilamide,6-dimethyl-4-pyrimidinyl)-
neazina
wln: t6n cnj bmswr dz& d1 f1
sulfadimerazine
nsc-67457
2-(p-aminobenzenesulfonamido)-4,6-dimethylpyrimidine
sulfadimidin
sa iii
sulfadimezine
n(sup1)-(4,6-dimethyl-2-pyrimidinyl)sulfanilamide
nci-c56600
diazil
sulphamidine
sulfamethiazine
diazil (the sulfanilamide)
2-sulfanilamido-4,6-dimethylpyrimidine
sulfadimethyldiazine
sulfadimidine
intradine
spanbolet
a-502
hava-span
6-(4'-aminobenzol-sulfonamido)-2,4-dimethylpyrimidin
neasina
sulmet
kelametazine
SPECTRUM_000990
SPECTRUM5_001270
OPREA1_677935
BSPBIO_000850
CBDIVE_012932
PRESTWICK3_000775
4-amino-n-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
sulfamethazine
nsc67457
nsc683529
[(4-aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine
57-68-1
PRESTWICK2_000775
OPREA1_142608
IDI1_000293
BSPBIO_003260
STK097514
NCGC00021490-03
sulfametazina [italian]
ccris 3701
einecs 200-346-4
sulfanilamide, n(sup 1)-(4,6-dimethyl-2-pyrimidinyl)-
(p-aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [german]
hsdb 4157
sulfadimezinum
sulfanilamide, n1-(4,6-dimethyl-2-pyrimidinyl)-
bn 2409
sulfadimidinum [inn-latin]
nsc 67457
sulfametazyny [polish]
sulka s boluses
sulfanilamide, n(sup1)-(4,6-dimethyl-2-pyrimidinyl)-
n(sup 1)-(4,6-dimethyl-2-pyrimidyl)sulfanilamide
4-amino-n-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide
ai3-26817
sulfadimidina [inn-spanish]
solfadimidina [dcit]
n(sup 1)-(4,6-dimethyl-2-pyrimidinyl)sulfanilamide
sulfanilamide, n(1)-(4,6-dimethyl-2-pyrimidinyl)-
sulfadimidine [inn:ban]
6-(4'-aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [german]
brn 0261304
calfspan tablets
sulfasure sr bolus
MLS000103403
sulfamethazine, >=99%
n(1)-(4,6-dimethyl-2-pyrimidinyl)sulfanilamide
2-(4-aminobenzenesulfonamido)-4,6-dimethylpyrimidine
n(1)-(4,6-dimethyl-2-pyrimidyl)sulfanilamide
4-amino-n-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide
SMZ ,
DB01582
sulfadimidine (inn)
sulfamezathine (tn)
D02436
sulfamethazine (usp)
NCGC00021490-05
NCGC00021490-06
NCGC00021490-04
smr000017409
KBIO3_002480
KBIOSS_001470
KBIOGR_000747
KBIO2_004038
KBIO2_001470
KBIO2_006606
SPECTRUM4_000344
SPBIO_001441
SPECTRUM3_001700
PRESTWICK0_000775
NCIOPEN2_003489
SPECTRUM2_001321
SPBIO_002789
NINDS_000293
PRESTWICK1_000775
SPECTRUM1500548
BPBIO1_000936
NCGC00018243-01
HMS2092I19
4-amino-n-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide
4,6-dimethylsulfadiazine
MLS002454449
CHEMBL446
sulfamidine
bn-2409
sulfamethazine (trisulfapyrimidines)
HMS500O15
FT-0655603
inchi=1/c12h14n4o2s/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7h,13h2,1-2h3,(h,14,15,16)
aswvtgncazcnnr-uhfffaoysa-
HMS1921A17
(p-aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin
sulfametazyny
sulfamethazone
sulfadimidinum
sulfametazina
sulfadimidina
CHEBI:102265 ,
NCGC00018243-07
AKOS000119894
4-amino-n-(4,6-dimethyl-2-pyridyl)benzenesulfonamide
A831551
NCGC00018243-08
NCGC00018243-06
NCGC00018243-04
NCGC00018243-03
NCGC00018243-02
NCGC00018243-05
4-amino-n-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide
C19530
dtxcid201290
tox21_303006
NCGC00256371-01
cas-57-68-1
dtxsid6021290 ,
NCGC00259770-01
tox21_202221
nsc-757326
nsc757326
pharmakon1600-01500548
tox21_110847
solfadimidina
CCG-39259
FT-0674743
unii-48u51w007f
sentry aq mardel biospheres maracyn plus
sulfamethazine [usp]
5-25-10-00250 (beilstein handbook reference)
48u51w007f ,
F1443-4796
EPITOPE ID:122238
S3133
neotrizine component sulfamethazine
sulfamethazine [usp monograph]
sulfadimidine [mart.]
sulfamethazine component of sulfaloid
lantrisul component sulfamethazine
sulfadimidine [who-ip]
sulfamethazine [usp-rs]
sulfadimidine [ep monograph]
trisulfapyrimidines (sulfamethazine) [orange book]
sulfamethazine component of lantrisul
sulfadimidinum [who-ip latin]
triple sulfoid component sulfamethazine
sulfamethazine component of sulfose
sulfamethazine [iarc]
sulfamethazine component of triple sulfoid
sulfadimidine [inn]
sulfaloid component sulfamethazine
sulfose component sulfamethazine
sulfamethazine [hsdb]
sulfamethazine component of terfonyl
sulfamethazine [orange book]
sulfadimidine [ep impurity]
terfonyl component sulfamethazine
sulfamethazine [green book]
sulfamethazine [vandf]
sulfamethazine component of neotrizine
trisulfapyrimidines (sulfamethazine)
sulfadimidine [who-dd]
HY-B0035
SCHEMBL151305
NCGC00018243-09
tox21_110847_1
MS-1576
cambridge id 5251384
W-105450
sulka k boluses
panazin
n1-(4,6-dimethyl-2-pyrimidyl)sulfanilamide
calfspan
2-(4-aminobenzenesulfonylamino)-4,6-dimethylpyrimidine
dimidim-r
s-dimidine
n1-(4,6-dimethyl-2-pyrimidinyl)sulfanilamide
diazilsulfadine
AB00052097_13
OPERA_ID_1374
AB00052097_12
mfcd00006066
sr-01000000211
SR-01000000211-3
sulfamethazine, united states pharmacopeia (usp) reference standard
sulfamethazine, vetranal(tm), analytical standard
HMS3652K03
sulfadimidine, european pharmacopoeia (ep) reference standard
sulfadimidine for peak identification, european pharmacopoeia (ep) reference standard
sulfamethazine, vetec(tm) reagent grade, >=99%
sulfamethazine 100 microg/ml in acetonitrile
SBI-0051522.P003
SW219689-1
sulfadimidine;sulfadimerazine
Q3976823
sulfadimidine,(s)
(4-amino-n-(4,6-dimethyl-2-pyrimidinyl)benzene sulfonamide
hsdb 4157; hsdb 4157; hsdb 4157;sulfadimidine;sulfadimerazine
BCP28439
EN300-16843
4-amino-n-(4
F85014
sulfadimidine for peak identification
gtpl12642
sulfamethazine 1000 microg/ml in acetonitrile
4-amino-n-(4,6-dimethyl-pyrimidin-2-yl)-benzene-13c6-sulfon-amide
sulfamethazine (iarc)
sustain iii calf
sulmet solution injectable
supra sulfa iii
sulfadimidine (mart.)
sulfamethazine spanbolet ii
sulfamethazine sustained release calf
sustain iii
4-amino-n-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonaminde
sulfatech sr
2-(p-aminobenzenesulfonamido)-4,6-dimethylpyridine
a 502
sulka-s bolus
sulfadimidinun (latin)
sulfadimidine (ep monograph)
j01eb03
sustain iii bolus, sustain iii calf bolus
sulmet drinking water solution, 12.5%
sulfamethazine (usp-rs)
sulfamethazine (usp monograph)
sulfadimidine (ep impurity)
sulmet oblets
sulfisomidon
azolmetazine
sulfamethazine sustained release
Z56791687

Research Excerpts

Overview

Sulfamethazine (SMZ) is an antibacterial drug used in approximately 75% of all hogs marketed in the U.S. It is a representative member of the sulfonamide antibiotic drugs; it is still used in human and veterinary therapy.

ExcerptReferenceRelevance
"Sulfamethazine (SMZ) is a type of SA widely used in the livestock and poultry industry."( Mechanism for biodegradation of sulfamethazine by Bacillus cereus H38.
Dong, Z; Kim, YM; Li, C; Wang, J; Wen, S; Yan, X; Zhang, W; Zhu, L, 2022
)
1.73
"Sulfamethazine is a representative member of the sulfonamide antibiotic drugs; it is still used in human and veterinary therapy. "( Thermodynamic Characterization of the Interaction between the Antimicrobial Drug Sulfamethazine and Two Selected Cyclodextrins.
Bognár, B; Kunsági-Máté, S; Lemli, B; Mohamed Ameen, H; Poór, M; Szente, L, 2019
)
2.18
"Sulfamethazine (SM2) is an antimicrobial drug that is frequently detected in manure compost, is difficult to degrade at high temperatures and is potentially threatening to the environment. "( Biodegradation of sulfamethazine by an isolated thermophile-Geobacillus sp. S-07.
Li, CX; Pan, LJ; Tang, XD; Wang, Y; Yu, GW, 2017
)
2.23
"Sulfamethazine (SMZ) (1) is an antibacterial sulfa drug which suppresses the synthesis of dihydrofolic acid. "( Sulphamethazine derivatives as immunomodulating agents: New therapeutic strategies for inflammatory diseases.
-Rahman, AU; Choudhary, MI; Haniffa, HM; Jabeen, A; Siddiqui, H, 2018
)
1.92
"Sulfamethazine (SMZ) is an ionizable and highly mobile antibiotic which is frequently found in soil and water environments. "( Acid-activated biochar increased sulfamethazine retention in soils.
Lee, SS; Ok, YS; Rajapaksha, AU; Thiele-Bruhn, S; Vithanage, M; Zhang, M, 2015
)
2.14
"Sulfamethazine (SMZ) is an antibacterial drug used in approximately 75% of all hogs marketed in the U.S. "( Sulfa residues in pork: an update.
Augsburg, JK, 1989
)
1.72

Effects

ExcerptReferenceRelevance
"Sulfamethazine (SMZ) has been widely used in animal husbandry and exposed to water and soil environments, posing potential threat to human health and ecological environment. "( Novel CoOOH-based fluorescent aptasensor for rapid and sensitive detection of sulfamethazine in environmental samples.
Chen, L; Le, T; Li, J; Peng, D; Sun, Q; Wang, Y; Zheng, X, 2024
)
3.11

Treatment

Sulfamethazine treatment induced a decrease in erythrocyte GSH concentration in all subjects.

ExcerptReferenceRelevance
"Sulfamethazine treatment induced a decrease in erythrocyte GSH concentration in all subjects."( Influence of double genetic polymorphism on response to sulfamethazine.
Atu-Taylor, LC; Woolhouse, NM, 1982
)
1.23
"Treatment with sulfamethazine apparently eradicated the infection from several herds."( Control of some internal parasites of chinchillas.
Hobson, NK; Stampa, S, 1966
)
0.58

Toxicity

ExcerptReferenceRelevance
" The crossover mating trial (task 3) revealed that the adverse effect on fertility involved both treated partners in that litter size decreased when either 1% SMZ males were bred to control females or 1% SMZ females were mated with control males."( Reproductive toxicity of sulfamethazine in Swiss CD-1 mice during continuous breeding.
Lamb, JC; Lawton, AD; Reel, JR; Tyl, RW, 1992
)
0.59
" These questions center on the suitability of the rodent model for agents that exert their toxic effects via specific enzyme interactions and endocrine mechanisms which appear to be inoperative within humans."( An FDA review of sulfamethazine toxicity.
Casciano, DA; Doerge, DR; Gaylor, DW; Kadlubar, FF; Lorentzen, RJ; Miller, MA; Poirier, LA; Schwetz, BA, 1999
)
0.64
" In general, efficient metabolite extraction from target cells is one of the keys to success to better understand the effects of toxic substances to organisms."( Significance of metabolite extraction method for evaluating sulfamethazine toxicity in adult zebrafish using metabolomics.
Cho, Y; De Sotto, R; Kim, S; Medriano, C; Park, Y; Seok, KS, 2016
)
0.68
" Toxicity assessment by means of Microtox method revealed the formation of some toxic intermediates during the treatment."( Pyrite as a sustainable catalyst in electro-Fenton process for improving oxidation of sulfamethazine. Kinetics, mechanism and toxicity assessment.
Ammar, S; Barhoumi, N; Brillas, E; Gadri, A; Olvera-Vargas, H; Oturan, MA; Oturan, N, 2016
)
0.66

Pharmacokinetics

The plasma and urine data obtained following intravenous administration of sulfamethazine to cattle were fit to a one-compartment pharmacokinetic model with a half-life of elimination of 9 hr and a volume of distribution of 0.

ExcerptReferenceRelevance
"The applications of pharmacokinetic modeling to the prediction of tissue residues of drugs in food-producing animals are reviewed."( Pharmacokinetic prediction of tissue residues.
Dittert, LW, 1977
)
0.26
"Previously reported plasma and urine concentrations of unchanged sulfamethazine and 3 metabolites following intravenous administration of sodium sulfamethazine to young ewe lamb were fitted to a linear pharmacokinetic model in which sulfamethazine itself obeyed 1-compartment phamacokinetics."( Disposition of sulfonamides in food-producing animals: pharmacokinetics of sulfamethazine in lambs.
Bevill, RF; Bourne, DW; Dittert, LW; Gural, RP; Sharma, RJ, 1977
)
0.72
" Antipyrine half-life in goats (2."( Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats.
Ali, BH; Elsheikh, HA; Hapke, HJ; Hassan, T; Homeida, AM, 1991
)
0.53
" At 20 degrees C a significantly lower level of distribution (Vdarea) and a significantly shorter elimination half-life (T(1/2)beta) was achieved in both species compared to the 10 degrees C level."( Pharmacokinetics of sulphadimidine in carp (Cyprinus carpio L.) and rainbow trout (Salmo gairdneri Richardson) acclimated at two different temperature levels.
Degen, M; Driessens, F; Grondel, JL; Nouws, JF; van Ginneken, VJ, 1991
)
0.28
" The pregnant uterus could not be recognised as an extra compartment, either in distribution volume nor in the pharmacokinetic model."( Influence of gestation on the pharmacokinetics of four sulphonamides in goats.
Van Deurzen, JM; Van Duin, CT; Van Gogh, H; Van Miert, AS, 1990
)
0.28
" The study revealed that the drug attained its peak concentration of 314."( Pharmacokinetics and distribution of sulphadimidine in plasma, milk and uterine fluid of female buffaloes.
Banerjee, NC; Jayachandran, C; Roy, GP; Singh, MK, 1988
)
0.27
" Both the Cmax and tmax of SMM and SMZ ranged widely."( Pharmacokinetics of oral sulfa drugs and gastric emptying in the pig.
Kokue, E; Sakurada, K; Shimoda, M; Wada, J, 1988
)
0.27
" Difference in elimination half-life of SMZ, SMR, and SDZ could be related to difference in metabolism and renal clearance values."( Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses.
Baakman, M; Firth, EC; Nouws, JF; Vree, TB, 1987
)
0.54
"The pharmacokinetic properties of three sulphonamides were determined in ruminant and preruminant kids after oral and intravenous administration."( Pharmacokinetics of three sulphonamides in ruminant and preruminant kids.
van Deurzen, EJ; van Duin, CT; van Gogh, H; van Miert, AS; Watson, AD, 1987
)
0.27
" The elimination half-life for SDM in carp was 17."( Fish and antibiotics: pharmacokinetics of sulphadimidine in carp (Cyprinus carpio).
Grondel, JL; Haenen, OL; Nouws, JF, 1986
)
0.27
" The infected goats had significantly prolonged elimination half-life values for sulphadimidine and oxytetracycline."( Chemotherapy and pharmacokinetics of some antimicrobial agents in healthy dwarf goats and those infected with Ehrlichia phagocytophila (tick-borne fever).
Anika, SM; Nieuwenhuijs, J; Nouws, JF; van Gogh, H; van Miert, AS; Vree, TB, 1986
)
0.27
"Pharmacokinetic studies in broilers and layers of different sulphonamides indicate a good absorption and a long elimination half-life (of sulphaquinoxaline, sulphadimidine and to a lesser degree sulphadiazine) resulting in high plasma concentrations during drinking water medication in the recommended therapeutic doses."( Some pharmacokinetic aspects of four sulphonamides and trimethoprim, and their therapeutic efficacy in experimental Escherichia coli infection in poultry.
de Jong, WA; Doornenbal, P; Goren, E, 1984
)
0.27
" The elimination half-life of the drug was similar in summer and winter, but the apparent volume of distribution was lower in summer."( Pharmacokinetics and urinary excretion of sulphadimidine in sheep during summer and winter.
Nawaz, M; Nawaz, R, 1983
)
0.27
" Further separation of the heterozygous rapid phenotype from the homozygous rapid phenotype has only been possible by detailed pharmacokinetic studies using sulphadimidine and necessitating prolonged plasma sampling."( A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.
Lee, EJ; Lee, LK, 1982
)
0.26
" A two-compartment pharmacokinetic model was developed to describe the disposition of these drugs."( Some pharmacokinetic and biochemical aspects of sulphadiazine and sulphadimidine in ewes.
Atef, M; El-Gendi, AY; El-Sayed, MG; Salam, SA; Youssef, SA, 1981
)
0.26
"The pharmacokinetic properties of sulphaperine-sodium, Mebacid 200, and sulphadimidine-sodium were experimentally established from fowl and mathematically objectivated."( [Pharmacokinetic studies of sulfamerazine-Na, sulfaperine-Na and sulfadimidine-Na in the hen].
Losch, K, 1980
)
0.26
" The formulation was given by deep intramuscular injection to pigs at doses of 10 mg kg-1 and 30 mg kg-1 and the pharmacokinetic properties were investigated."( Pharmacokinetics of baquiloprim and sulphadimidine in pigs after intramuscular administration.
Davies, AM; MacKenzie, NM, 1994
)
0.29
" The half-life of SDM was increased from 15."( Pharmacokinetics of ampicillin and sulfadimidine in pigs infected experimentally with Streptococcus suum.
Miao, XQ; Yin, YH; Yuan, ZH, 1997
)
0.3
"Sulphamonomethoxine (SMM), sulphadimidine (SDD), sulphadiazine (SDZ) and their N4-acetyl derivatives (AcSMM, AcSDD and AcSDZ) were intravenously injected into Goettingen miniature pigs and deacetylation was evaluated from plasma concentration-time curves, renal excretion, and rate constants obtained from pharmacokinetic analysis, using a non-linear least-squares method."( Deacetylation as a determinant of sulphonamide pharmacokinetics in pigs.
Fujii, C; Okamoto, K; Shimoda, M; Sikazwe, G; Son, DS, 1997
)
0.3
"The effect of water deprivation on the pharmacokinetic parameters of antipyrine and sulphadimidine in the Nubian goat was studied."( The effect of water deprivation on the pharmacokinetics of antipyrine and sulphadimidine following intravenous administration in Nubian goats.
Abdullah, AS; Elsheikh, HA; Osman, IA, 1997
)
0.3
" Pharmacokinetic variables obtained for sulfamethazine in plasma and in saliva were closely related (AUC 1408 micrograms."( Comparative pharmacokinetics of sulfamethazine in plasma and parotid saliva of sheep.
Boivin, R; Meot, F; Pulido, E; Sumano, H, 1998
)
0.85
" Analysis of the intravenous data according to a two-compartment pharmacokinetic model revealed that SDM was well distributed in the body (Vd(area):0."( Pharmacokinetics, bioavailability and dosage regimen of sulphadimidine in camels (Camelus dromedarius) under hot, arid environmental conditions.
Kumar, R; Rai, AK; Singh, AP,
)
0.13
"The pharmacokinetic aspects of sulphadimidine were studied in clinically healthy (control) and Flunixin-medicated horses after a single intravenous and oral administration of 100 mg/kg body weight."( Pharmacokinetic interactions between flunixin and sulphadimidine in horses.
el-Banna, HA, 1999
)
0.3
"To develop a flow-limited, physiologic-based pharmacokinetic model for use in estimating concentrations of sulfamethazine after IV administration to swine."( Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues.
Baynes, RE; Buur, JL; Craigmill, AL; Riviere, JE, 2005
)
0.77
" Probabilistic modeling techniques incorporated into a physiologically based pharmacokinetic (PBPK) model were used to predict the amounts of sulfamethazine residues in edible tissues in swine."( Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine.
Baynes, R; Buur, J; Riviere, J; Smith, G, 2006
)
0.75
" Pharmacokinetic values, which were calculated using a first-order one-compartment model, residue levels and transfer rates into the eggs were found to be dose-dependent."( A sulfadimidine model to evaluate pharmacokinetics and residues at various concentrations in laying hen.
Kietzmann, M; Niedorf, F; Tansakul, N, 2007
)
0.34
" Noncompartmental-based pharmacokinetic model parameters for clearance, half-life, and volume of distribution were consistent with previously published values in swine."( Sulfamethazine water medication pharmacokinetics and contamination in a commercial pig production unit.
Almond, GW; Baynes, RE; Buur, JL; Mason, SE; Riviere, JE, 2008
)
1.79
" Differences were found between one-three-weeks-old calves and seven-fifteen-weeks-old calves, in pharmacokinetic parameters (clearance, area under the concentration-time curve and elimination half-life) and in the PK/PD integration."( Effects of age on the pharmacokinetics of single dose sulfamethazine after intravenous administration in cattle.
Baroni, EE; Boggio, JC; Díaz, DC; Picco, E; Rodríguez, C; San Andrés, MI; Waxman, S, 2008
)
0.59
" There is a need for a pharmacokinetic modeling technique that can predict the consequences of possible drug interactions."( A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition.
Baynes, RE; Buur, JL; Riviere, JE; Smith, GW, 2009
)
0.35
" Within-drug and metabolite analysis of pharmacokinetic parameters included fixed effects of drug administration date, sex and breed of sire."( The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine.
Ashwell, MS; Baynes, RE; Bellis, B; Brooks, JD; Howard, JT; Maltecca, C; O'Nan, AT; Routh, P; Yeatts, JL, 2014
)
0.69

Compound-Compound Interactions

ExcerptReferenceRelevance
" On the basis of literature data six sulphonamides, sulphadiazine, sulphachloropyridazine, sulphamethoxazole, sulphaisodimidine, sulphamerazine and sulphamethomidine appeared particularly suitable for combination with trimethoprim."( Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim.
Bergan, T; Ekström, B; Forsgren, U; Ortengren, B, 1979
)
0.26
"Experiments on white rats showed that single administration of sulfadimesin or sulfamonomethoxin combined with UV irradiation delays absorption, increases acetylation rate and diminishes excretion of the drugs with urine."( [Sulfadimezine and sulfamomomethoxine distribution in the body of white rats in single and repeated administration in combination with UV irradiation].
Matveeva, SA,
)
0.13
" Sulfamoxole (SMO), Sulfadiazine (SDZ) and Sulfadimidine (SDD) in combination with trimethoprim (TMP) were studied in 12 healthy volunteers."( Comparative pharmacokinetic study of four different sulfonamides in combination with trimethoprim in human volunteers.
Garg, SK; Ghosh, SS; Mathur, VS, 1986
)
0.27
"Chronic treatment with sulfadimesin or sulfamonomethoxin combined with UV irradiation leads to potentiation of adrenocortical function."( [Several indices of the functional state of the adrenals of white rats during a prescribed course of sulfadimezine and sulfamonomethoxine combined with UV-irradiation].
Matveeva, SA,
)
0.13

Bioavailability

The absorption rate constant (Kab) of each sulfonamide increased with increase in temperature. At each temperature, Kab was the highest for sulfamethazine and the lowest for sulfadiazine. Equilibrating soil samples with metolachlor solutions did not lead to any significant effects on metolchlor sorption. After 45 d the denitrification rate, MPN and gene copy numbers were similar to that of the no-chemical control.

ExcerptReferenceRelevance
"The bioavailability of seven commercial trisulfapyrimidine suspensions was studied in 14 adult male volunteers."( Bioavailability and dissolution behavior of trisulfapyrimidine suspensions.
Barry, H; Colaizzi, JL; Goehl, TJ; Jaffe, JM; Mathur, LK; Poust, RI; Shah, VP, 1979
)
0.26
" Specifically, a dose-dependent decrease in absorption rate displaced the plasma concentration-time curve to the right in some subjects, whereas apparent metabolic clearance (Clm) decreased with increasing dose (estimated assuming dose = amount of SMZ + NSMZ in urine to 72 hr) in all subjects (0."( Mechanisms of nonlinear disposition kinetics of sulfamethazine.
du Souich, P; Elvin, AT; Lalka, D; McLean, AJ; Slaughter, R, 1979
)
0.52
" The mean bioavailability of the oral SMZ solution was 58."( Pharmacokinetics, safety and tissue residues of sustained-release sulfamethazine in sheep.
Archer, TE; Baggot, JD; Bulgin, MS; Craigmill, AL; Lane, VM, 1991
)
0.52
" Bioavailability after oral administration was approximately 100% of sulphadiazine, but only about 60% for TMP."( Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers.
Fassbender, CP; Kietzmann, M; Löscher, W; Weissing, M, 1990
)
0.28
"07 h-1) and SMZ bioavailability was not affected at all."( Sulfamethazine absorption and disposition: effect of surgical procedures for gastroduodenal ulcers.
Calvo, R; Carlos, R; Du Souich, P; Sarabia, S,
)
1.57
" Of the three drugs tested, SDX might be the most satisfactory for therapeutic use in preruminant animals, because it has good bioavailability after oral administration and long t1/2(el)."( Pharmacokinetics of three sulphonamides in ruminant and preruminant kids.
van Deurzen, EJ; van Duin, CT; van Gogh, H; van Miert, AS; Watson, AD, 1987
)
0.27
" The bioavailability of SDM administered in a drench was 88."( Pharmacokinetics, renal clearance, tissue distribution, and residue aspects of sulphadimidine and its N4-acetyl metabolite in pigs.
Baakman, M; Driessens, F; Mevius, DJ; Nouws, JF; Vellenga, L; Vree, TB, 1986
)
0.27
" No differences were observed in the rate of sulfamethazine absorption, but bioavailability was decreased when compared with control subjects."( Influence of chronic obstructive lung disease on the disposition of an acidic drug (sulfamethazine).
Amyot, R; Desjardins, R; du Souich, P; Julien, M; Latour, J; Leblanc, P, 1983
)
0.75
"A simple equation is proposed to estimate the apparent absorption rate constant (Ka)."( Drug absorption: a practical method to estimate the absorption rate constant.
du Souich, P; Lambert, C, 1981
)
0.26
" The absorption rate constant (Kab) of each sulfonamide increased with increase in temperature and, at each temperature, Kab was the highest for sulfamethazine and the lowest for sulfadiazine."( Elucidation of the role of hydrophobic bonding in influencing intestinal absorption of model sulfonamides and revealing possible mechanism of drug absorption in rat model.
Chow, SL; Nagwekar, JB, 1993
)
0.49
" Bioavailability after oral administration was 85."( Pharmacokinetic model for predicting sulfamethazine disposition in pigs.
Bardalaye, PC; Smith, CM; Soma, LR; Sweeney, RW; Uboh, CE, 1993
)
0.56
" The extent of bioavailability remained unchanged."( Effects of nocloprost (9 beta-chloro-16,16-dimethyl PG E2) on absorption and disposition of antipyrine and sulfamethazine in healthy volunteers.
Amon, I; Franke, G; Müller, C; Siegmund, W; Zschiesche, M, 1993
)
0.5
" In adult animals, or in the young of other animal species in which digesta transit time is slower than in calves, the bioavailability of microgranulated sulfadimidine may be much greater."( Relative bioavailability of microgranulated sulfadimidine in veal calves.
Anfossi, P; Formigoni, A; Montesissa, C; Pezzi, P, 1996
)
0.29
"The bioavailability of two different forms of medicated feed containing 2000 mg sulfadimidine (SDM) per kg was determined in three groups of eight piglets."( Sprayed medicated feed with sulfadimidine for piglets.
Küng, K; Riond, JL; Wanner, M, 1996
)
0.29
" The mean bioavailability of SDM following oral administration was approximately 100%."( Pharmacokinetics, bioavailability and dosage regimen of sulphadimidine in camels (Camelus dromedarius) under hot, arid environmental conditions.
Kumar, R; Rai, AK; Singh, AP,
)
0.13
" Equilibrating soil samples with metolachlor solutions containing equivalent sulfamethazine concentrations did not lead to any significant effects on metolachlor sorption, suggesting that, under the conditions of the present experiment, sulfamethazine did not affect metolachlor bioavailability in soil."( Effects of the antimicrobial agent sulfamethazine on metolachlor persistence and sorption in soil.
Accinelli, C; Epifani, R; Hashim, M; Schneider, RJ; Vicari, A, 2006
)
0.84
" The lower persistence of the antimicrobials in liquid swine slurry-amended soil was likely due to higher microbial activity, as compared to unamended soil, and/or to the greater bioavailability of the sulfonamides to degrading microorganisms, as estimated by sorption isotherms."( Environmental fate of two sulfonamide antimicrobial agents in soil.
Accinelli, C; Becker, JM; Koskinen, WC; Sadowsky, MJ, 2007
)
0.34
"Formulations containing amorphous active pharmaceutical ingredients (APIs) present great potential to overcome problems of limited bioavailability of poorly soluble APIs."( A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron, V; Corrigan, OI; Healy, AM; Tajber, L, 2011
)
0.37
" However, after 45 d the denitrification rate, MPN and gene copy numbers for sulfamethazine and enrofloxacin were similar to that of the no-chemical control, indicating that acclimation of the denitrifier population to the antibiotic or reduced bioavailability over time allowed recovery of the denitrifier population."( Dissipation of atrazine, enrofloxacin, and sulfamethazine in wood chip bioreactors and impact on denitrification.
Ilhan, ZE; Moorman, TB; Ong, SK,
)
0.62
"Adsorption and desorption are important processes that influence the transport, transformation and bioavailability of antimicrobials in soils."( Sorption and desorption of sulfadimethoxine, sulfaquinoxaline and sulfamethazine antimicrobials in Brazilian soils.
Doretto, KM; Peruchi, LM; Rath, S, 2014
)
0.64
" The mean oral bioavailability of sulfadiazine was high (83."( Oral absorption profiles of sulfonamides in Shiba goats: a comparison among sulfadimidine, sulfadiazine and sulfanilamide.
Aboubakr, M; Elbadawy, M; Ishihara, Y; Sasaki, K; Shimoda, M, 2016
)
0.43
" Therefore, the abundant DOM released from phytoplankton and macrophytes affected the transport of antibiotics to sediments and might eventually change their bioavailability and toxicity to organisms."( Roles of phytoplankton- and macrophyte-derived dissolved organic matter in sulfamethazine adsorption on goethite.
Bai, L; Cao, C; Jiang, H; Wang, C; Zhang, H, 2017
)
0.69
" aureus, (iii) larger oral absorption and bioavailability (2."( Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating.
Bolas-Fernandez, F; Dea-Ayuela, MA; Galiana, C; Healy, AM; Mugheirbi, NA; O'Connell, P; Serrano, DR; Walsh, D; Worku, ZA, 2018
)
0.48
" The purpose of the present study was to assess the bioavailability of sulfamethazine, erythromycin, or ciprofloxacin through aqueous extractions with borax or EDTA solutions and their biodegradation following different soil exposure scenarios."( Explaining the accelerated degradation of ciprofloxacin, sulfamethazine, and erythromycin in different soil exposure scenarios by their aqueous extractability.
Asghar, F; Benoit, P; Goulas, A; Haudin, CS; Sabourin, L; Topp, E, 2018
)
0.96
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Cows were dosed orally (n = 4) or intravenously with sulfamethazine. Thyroid gland enlargement was evident at necropsy in one half of the rats (12 of 24) which received the 3600 ppm dosage level.

ExcerptRelevanceReference
" The knowledge of this fact is of great importance, and should be taken into consideration in the calculation of proper dosage of various drugs in the newborns and infants."( [Binding capacity of some drugs to plasma proteins of newborns in comparison with adults (author's transl)].
Bozkowa, K; Hofman, H; Piekarczyk, A; Prokopczyk, J; Wańkowicz, B, 1977
)
0.26
" This principle is applied for the stability-indicating determination of sulfacetamide in the presence of sulfanilamide, sulfaquinoxaline in feed, and sulfabromomethazine in dosage forms."( Facile separation of sulfonamides from their degradates by liquid--liquid extraction.
Blodinger, J; Fink, DW; Martin, RP, 1978
)
0.26
" The safety of the sustained-release preparation was tested by dosing sheep with multiples (one, three and five times) of the recommended dose (one tablet, 8 g SMZ, per 20 kg body wt), once a day for 3 days."( Pharmacokinetics, safety and tissue residues of sustained-release sulfamethazine in sheep.
Archer, TE; Baggot, JD; Bulgin, MS; Craigmill, AL; Lane, VM, 1991
)
0.52
" A comparison between the single and the "cocktail" dosage did not reveal any significant differences in the pharmacokinetic parameters."( [Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases].
Henschel, L; Hoffmann, A; Huster, A; Jorke, D; Kraul, H; Reinhardt, M; Töpfer, R; Truckenbrodt, J, 1990
)
0.28
" Oral dosing of TMP in combination with sulphadimidine yielded similar maximum plasma concentrations of both compounds to those obtained with the combination of TMP with sulphadiazine, but the plasma concentration decline of sulphadimidine appeared to be more rapid than that of sulphadiazine after oral administration."( Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers.
Fassbender, CP; Kietzmann, M; Löscher, W; Weissing, M, 1990
)
0.28
" No difference in feed consumption was found between the control and dosed rats."( Chronic toxicity/carcinogenicity studies of sulphamethazine in Fischer 344/N rats: two-generation exposure.
Allen, R; Gaylor, DW; Littlefield, NA; Sheldon, WG, 1990
)
0.28
"Disposition kinetics and dosage regimen of sulphamethazine were investigated in sheep following single intravenous administration (100 mg/kg)."( Disposition kinetics and dosage regimen of sulphamethazine in sheep (Ovis aries).
Rampal, S; Srivastava, AK,
)
0.13
" The dosages for maintaining concentration of 50 micrograms/ml, 100 micrograms/ml and 150 micrograms/ml at convenient dosage intervals of 12 and 24 h were also determined."( Pharmacokinetics and distribution of sulphadimidine in plasma, milk and uterine fluid of female buffaloes.
Banerjee, NC; Jayachandran, C; Roy, GP; Singh, MK, 1988
)
0.27
" The mean conclusion is that dosage of drugs with elimination by acetylating reaction needs precaution in patients with liver diseases."( Sulfadimidine kinetics in patients with various chronic liver diseases.
Horváth, T; Jávor, T; Kádas, I; Par, A; Past, T,
)
0.13
"The identification of patients as 'fast acetylators' or 'slow acetylators' is used in clinical practice to help recognize those at risk from toxicity and in guiding the dosage of N-acetylated drugs."( Caffeine as a potential indicator for acetylator status.
Fell, AF; Hudson, SA; Rankin, RB, 1987
)
0.27
" The methanol-insoluble 14C-labelled residues in the gut of rats dosed orally with 14C-SDTFB and 14C-sulmet + nitrite were partially converted to 14C-labelled desaminosulmet, sulmet, N4-acetylsulmet and other unidentified products when fed to recipient rats."( Formation of a diazonium cation intermediate in the metabolism of sulphamethazine to desaminosulphamethazine in the rat.
Feil, VJ; MacGregor, JT; Paulson, GD, 1987
)
0.27
"05) for females dosed at 1200 and 2400 ppm for 18 mo and for males dosed at 600, 1200, or 2400 ppm sulfamethazine for 24 mo than for those dosed at levels of 40 ppm or less."( Influence of oral administration of sulfamethazine on thyroid hormone levels in Fischer 344 rats.
Fullerton, FR; Kushmaul, RJ; Littlefield, NA; Suber, RL, 1987
)
0.76
"Pharmacokinetics and tissue distribution experiments were conducted in pigs to which sulphadimidine (SDM) was administered intravenously, orally, and intramuscularly at a dosage of 20 mg SDM/kg."( Pharmacokinetics, renal clearance, tissue distribution, and residue aspects of sulphadimidine and its N4-acetyl metabolite in pigs.
Baakman, M; Driessens, F; Mevius, DJ; Nouws, JF; Vellenga, L; Vree, TB, 1986
)
0.27
"Plasma disposition, protein binding, urinary recovery, and renal clearance of sulfamethazine (SMZ), its N4-acetylsulfamethazine (N4-SMZ), and its 2 hydroxy metabolites--6-hydroxymethylsulfamethazine (SCH2OH) and 5-hydroxysulfamethazine (SOL)--and the glucuronide of the latter were studied in 7 cows and 7 calves to determine the relationship between these values and the age of the animal and dosage applied."( Age and dosage dependency in the plasma disposition and the renal clearance of sulfamethazine and its N4-acetyl and hydroxy metabolites in calves and cows.
Baakman, M; Breukink, HJ; Driessens, F; Mevius, D; Nouws, JF; Vree, TB, 1986
)
0.73
"Fractional acetylation of plasma sulphadimidine 6 h after dosing with 40 mg/kg metabolically active mass (p."( Acetylator phenotype in patients with lung carcinoma--a negative report.
Burgess, EJ; Trafford, JA, 1985
)
0.27
" The percentage of the 14C remaining in the animals after dosing was as follows: 6 hr, 88%; 24 hr, 49%; 48 hr, 14%; 192 hr, less than 1%."( The isolation and identification of 14C-sulfamethazine (4-amino-n-(4,6-dimethyl-2-pyrimidinyl)[14C]benzenesulfonamide) metabolites in the tissues and excreta of swine.
Giddings, JM; Lamoureux, CH; Mansager, ER; Paulson, GD; Struble, CB,
)
0.4
" The aim of our studies on patients with various chronic liver diseases was to get information about the rational dosage for these patients."( Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
Horváth, T; Jávor, T; Kádas, I; Pár, A; Past, T; Tapsonyi, Z; Tatai, Z,
)
0.13
" As a consequence there are no grounds for reducing the dosage of isoniazid given to patients with impaired renal function."( [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
Ellard, GA, 1984
)
0.27
" Thyroid gland enlargement was evident at necropsy in one half of the rats (12 of 24) which received the 3600 ppm dosage level of sulfamethazine and in 1 of 24 rats fed the 2400 ppm level."( Effect of subchronic oral sulfamethazine administration on Fischer 344 rats and B6C3F1 mice.
Heath, JE; Littlefield, NA, 1984
)
0.77
" She recovered after surgical drainage of the abscesses and prolonged treatment with intravenous amikacin and high dosage cotrimoxazole and sulphadimidine."( Abdominal nocardiosis in a Sudanese girl.
Dickson, JA; Duerden, BI; Milner, RD; Salfield, SA, 1983
)
0.27
" The results have been evaluated from the methodological aspect to work out an appropriate dosage regime in liver diseases."( Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Beró, T; Fábián, C; Horváth, T; Jávor, T; Kádas, I; Pár, A, 1983
)
0.27
" nonsmoking state, as measured by %ASMZ in serum six hours post-SMZ dosing or by %ASMZ in urine five to six hours post-SMZ dosing."( No effect of smoking on sulfamethazine acetylation.
Cosgriff, JM; Miller, ME,
)
0.44
" Based on these studies a satisfactory intravenous dosage regimen might consist of 86 and 100 mg/kg for priming and 78 and 88 mg/kg as maintenance doses during summer and winter, respectively, the doses being repeated at 12 hour intervals."( Pharmacokinetics and urinary excretion of sulphadimidine in sheep during summer and winter.
Nawaz, M; Nawaz, R, 1983
)
0.27
" Within a phenotypic mode, body weight may be useful in providing initial estimates of dosing needs."( Potential influence of body weight on the clearance of polymorphically acetylated drugs.
Chapron, DJ; Kramer, PA; Mercik, SA,
)
0.13
" The investigation revealed that the dosage regimen of sulphadimidine did not differ significantly between normal and febrile dogs."( Pharmacokinetics of sulphadimidine in normal and febrile dogs.
Nawaz, M; Riffat, S, 1982
)
0.26
"Recent investigations have clearly established the presence of desaminosulfamethazine (I), N4-acetylsulfamethazine (II), and N4-D-glucosyl sulfamethazine (III) in the tissues of swine which have been dosed with sulfamethazine (V)."( Evaluation of three methods for recovery of sulfamethazine metabolites from swine tissue.
Barnes, CJ; Fazio, T; Matusik, JE; Newkirk, DR, 1982
)
0.76
" This study shows that the metabolic alterations of alloxan induced diabetes in dogs, influence the drug disposition and urinary excretion which indicate the need for the adjustment of dosage regimen in such metabolic disorders."( Disposition kinetics and urinary excretion of sulphadimidine in normal and alloxan diabetic dogs.
Akhtar, S; Hashmi, AS; Nawaz, M, 1982
)
0.26
" The applicability of acetylator phenotyping for individualization of hydralazine dosage regimens merits further evaluation."( Plasma concentration and acetylator phenotype determine response to oral hydralazine.
Lin, MS; Ludden, TM; McNay, JL; Musgrave, GE; Shepherd, AM,
)
0.13
" Analytical chemical procedures that would ensure proper concentration, homogeneity, and stability of the drug in dosed feed and its safe usage during the animal studies were prerequisites for such toxicological tests."( Trace analysis of sulfamethazine in animal feed, human urine, and wastewater by electron capture gas chromatography.
Bowman, MC; Holder, CL; Thompson, HC, 1981
)
0.6
"05) when the two methods of drug dosing were compared."( Sulfamethazine residues in swine.
Bevill, RF; Biehl, LG; Koritz, GD; Limpoka, M, 1981
)
1.71
" The metabolism of [14C]benzoate and of p-aminobenzoic acid in the neonatal marmoset was compared with that in similarly dosed neonatal rats."( Some pathways of xenobiotic metabolism in the adult and neonatal marmoset (Callithrix jacchus).
Hall, BE; James, SP, 1980
)
0.26
" Based on this study we suggest an intravenous dosage regimen consisting of 38."( Pharmacokinetics of sulfamethazine in buffaloes.
Anwar-Ul-Hassan, S; Khan, FH; Nawaz, M, 1980
)
0.58
" These data were used in dosage calculations for clinical testing."( [Pharmacokinetic studies of sulfamerazine-Na, sulfaperine-Na and sulfadimidine-Na in the hen].
Losch, K, 1980
)
0.26
" Nine similar calves were also infected in the same manner after dosing six hours previously with a bolus providing doses of 4 mg/kg baquiloprim and 36 mg/kg sulphadimidine."( Administration of a bolus formulation of baquiloprim and sulphadimidine to calves: plasma concentration--time profiles and efficacy in suppressing experimental pneumonic pasteurellosis.
Dassanayake, L; White, G, 1994
)
0.29
"Cows were dosed orally (n = 4) or intravenously (n = 4) with sulfamethazine [sulmet; 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide] for 5 consecutive days (220 mg/kg of body weight on day 1 and 110 mg/kg on days 2-5)."( Depletion of residues from milk and blood of cows dosed orally and intravenously with sulfamethazine.
Feil, VJ; Giddings, JM; Paulson, GD; Slanger, WD; Zaylskie, RG,
)
0.6
" Blind samples included raw milk fortified with SMZ at 10 and 20 ppb and 1 sample containing SMZ residue from a dosed cow."( Liquid chromatographic method for determination of sulfamethazine residues in milk: collaborative study.
Smedley, MD; Weber, JD,
)
0.38
" rBST was given subcutaneously at a dose of 250 or 500 micrograms 100 g-1 bodyweight 24 h-1 in different dosage patterns."( Selective changes in oxidative xenobiotic metabolism in vivo and in vitro after parenteral administration of recombinant bovine somatotrophin to rats.
Kolker, HJ; Nijmeijer, SM; Noordhoek, J; van Miert, AS; Witkamp, RF, 1993
)
0.29
"Sulfamethazine (SMZ) ip administration for 3 d to chickens showed significant induction of cytochrome P-450 levels and in the activities of aminopyrine N-demethylase, aniline hydroxylase and glutathione s-transferase at the dosage of 150 mg SMZ/kg body weight."( Effect of sulfamethazine on mixed function oxidase in chickens.
Govindwar, SP; Kodam, KM, 1995
)
2.14
" Our results suggest that, if the label withdrawal period of 10 days is observed, an increase in the dosage of up to three times the recommended rate is unlikely to increase significantly the risk that residues would occur in the tissues of treated hogs at concentrations which exceed MRLs."( Residue depletion in tissues and fluids from swine fed sulfamethazine, chlortetracycline and penicillin G in combination.
Fesser, AC; Korsrud, GO; MacNeil, JD; Papich, MG; Salisbury, CD, 1996
)
0.54
"The kinetics of free and microgranulated sulfadimidine were compared in milk-fed calves dosed orally (180 mg/kg) in a crossover study."( Relative bioavailability of microgranulated sulfadimidine in veal calves.
Anfossi, P; Formigoni, A; Montesissa, C; Pezzi, P, 1996
)
0.29
" Sulphadimidine-containing tissue powders (400 vials each of muscle, liver and kidney) were prepared by orally dosing pigs with drug, producing lyophilized tissue powders and blending these with negative tissues from unmedicated animals to achieve target concentrations."( The production of pig tissue sulphadimidine reference material.
Crooks, SR; Elliott, CT; Hewitt, SA; McCaughey, WJ; McEvoy, JD,
)
0.13
" The inducer dose of 150 mg SMZ/kg and the inhibitory dose of 300 mg SMZ/kg were selected for dosing young male, old male and adult female rats."( In vivo and in vitro effect of sulfamethazine on hepatic mixed function oxidases in rats.
Govindwar, SP; Kodam, KM, 1997
)
0.58
" It should be taken into account when dosing drugs which are metabolized as markers of the liver metabolic efficiency like phenazone and sulphadimidine."( [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Kotlarek-Haus, S; Milejski, P; Orzechowska-Juzwenko, K; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wiela-Hojeńska, A, 1997
)
0.3
" In short-term mechanistic studies in rats there was a log-dose response relationship in circulating levels of thyroid and pituitary hormones plus a similar non-linear dose-response in morphologic changes in thyroid follicular cells."( Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system.
Capen, CC, 1998
)
0.3
"A two-way crossover study was conducted in young Bikaneri camels (aged between 12 and 18 months) during the hot summer season to determine the bioavailability, pharmacokinetics and dosage regimens of sulphadimidine (SDM)."( Pharmacokinetics, bioavailability and dosage regimen of sulphadimidine in camels (Camelus dromedarius) under hot, arid environmental conditions.
Kumar, R; Rai, AK; Singh, AP,
)
0.13
" Only by increasing the dosage of antibiotics to a therapeutic level does antibiotic metaphylaxis surpass homeopathic metaphylaxis."( Homeopathy versus antibiotics in metaphylaxis of infectious diseases: a clinical study in pig fattening and its significance to consumers.
Albrecht, H; Schütte, A, 1999
)
0.3
" The routine antibiotic dosage of metaphylaxis is too low to be effective."( Homeopathy versus antibiotics in metaphylaxis of infectious diseases: a clinical study in pig fattening and its significance to consumers.
Albrecht, H; Schütte, A, 1999
)
0.3
" Based on this study, an optimal dosage regimen of sulphadimidine in buffalo calves would be 100 mg/kg, followed by 50 mg/kg at 12 h intervals."( Pharmacokinetics and urinary excretion of sulphadimidine in buffalo calves.
Garg, BD; Jain, SK; Punia, JS, 2000
)
0.31
" The transfected cells were dosed with 4-aminosalicylic acid, sulfamethazine or solvent and the resulting luciferase activity was measured."( Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes.
Mitchell, KR; Warshawsky, D, 2003
)
0.56
" Within a short time of dosing such animals, there is little or none of the uncombined drug in the blood."( The treatment of experimental toxoplasmosis in rabbits.
BEVERLEY, JK; FRY, BA, 1957
)
0.24
" In this study, the three spectrophotometric methods can be satisfactorily used for the quantitative analysis and for dissolution tests of multicomponent dosage forms."( Chemometric and derivative methods as flexible spectrophotometric approaches for dissolution and assaying tests in multicomponent tablets.
Koundourellis, JE; Malliou, ET; Markopoulou, CK, 2004
)
0.32
"The goal of this study was to assess the utility of near infrared (NIR) spectroscopy for the determination of content uniformity, tablet crushing strength (tablet hardness), and dissolution rate in sulfamethazine veterinary bolus dosage forms."( Assessment of NIR spectroscopy for nondestructive analysis of physical and chemical attributes of sulfamethazine bolus dosage forms.
Bensley, D; Fahmy, R; Hoag, SW; Hollenbeck, G; Hussain, AS; Marnane, W; Tatavarti, AS; Wu, H, 2005
)
0.73
" A PBPK model for sulfamethazine in swine was adapted to include an oral dosing route."( Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine.
Baynes, R; Buur, J; Riviere, J; Smith, G, 2006
)
0.89
"The bolus (or oblet) is a dosage form that can be used for the oral administration of pharmaceutical compounds to ruminating species."( Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles.
Bensley, D; Fahmy, R; Hoag, S; Howard, KD; Kawalek, JC; Marnane, W; Marroum, P; Martinez, MN; Pelsor, FR; Tatavarti, AS; Ward, JL; Xie, L, 2006
)
0.58
" The ratios obtained in PK/PD integration (T>MIC, WAUC) confirm that it is necessary to apply twice the dose of sulfamethazine in > or = 7 weeks-old cattle to reach a satisfactory dosage regimen (MIC > or = 32 microg/mL)."( Effects of age on the pharmacokinetics of single dose sulfamethazine after intravenous administration in cattle.
Baroni, EE; Boggio, JC; Díaz, DC; Picco, E; Rodríguez, C; San Andrés, MI; Waxman, S, 2008
)
0.81
" Ultimately it could be used in the design of dosing regimens and in the protection of the food supply through prediction and minimization of tissue residues."( A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition.
Baynes, RE; Buur, JL; Riviere, JE; Smith, GW, 2009
)
0.35
" Finally this BIACORE method was able to detect positive samples containing sulfamethazine in the dosing range between 50 and 150 ng/ml."( Use of the total error approach to evaluate the performance of a semi-quantitative immunological method (BIACORE method) for detecting sulfamethazine in bovine milk.
Gaudin, V; Laurentie, M, 2009
)
0.79
" The amorphous complexes obtained in this study may be useful in the preparation of pharmaceutical dosage forms of SMT."( Binding of sulfamethazine to β-cyclodextrin and methyl-β-cyclodextrin.
Aiassa, V; Delrivo, A; Longhi, MR; Zoppi, A, 2013
)
0.78
" Increasing carbon dosage and contact time enhanced the removal of micropollutants."( Adsorption characteristics of selected hydrophilic and hydrophobic micropollutants in water using activated carbon.
Choi, DJ; Her, N; Kim, SK; Nam, SW; Zoh, KD, 2014
)
0.4
" Thus, this work addresses the degradation of SMT in water solutions (12 L of 25mgL-1 samples) by means of a photo-Fenton process and a systematic H202 dosage protocol that enhances its performance."( Degradation of sulphamethazine by means of an improved photo-Fenton process involving a hydrogen peroxide systematic dosage.
González, LP; Graells, M; Pérez-Moya, M; Yamal-Turbay, E, 2014
)
0.4
" In this study, withdrawal intervals (WDI) were estimated for pigs when dosed with tetracycline and sulfamethazine in water."( Tissue concentrations of sulfamethazine and tetracycline hydrochloride of swine (Sus scrofa domestica) as it relates to withdrawal methods for international export.
Baynes, RE; Mason, SE; Wu, H; Yeatts, JE, 2015
)
0.94
" Intravenous administration of trimethoprim (5 mg/kg) and sulfadimidine (25 mg/kg) proved likely to be efficient for treating sinusitis caused by highly susceptible pathogens, providing that the dosing interval is 12 hours."( Application of in vivo microdialysis for investigation of unbound drug concentrations of intravenously administered sulfadimidine in the paranasal sinus mucosa of horses.
Bienert-Zeit, A; Gietz, C; Kietzmann, M; Ohnesorge, B; Stahl, J; Staszyk, C, 2015
)
0.42
" These results provided an integrated perspective on assessing the toxicity effects of antibiotic in non-lethal dosage on the feeding behavior of non-target aquatic organisms."( Correlation between antibiotic-induced feeding depression and body size reduction in zooplankton (rotifer, Brachionus calyciflorus): Neural response and digestive enzyme inhibition.
Chen, J; Guo, R; Tang, S; Torres, OL; Wang, X; Yan, Z; Yang, Q; Zhang, S, 2019
)
0.51
" With higher dosage and longer exposure time, the toxic effect of single and combined contaminants on soil bacteria, fungi and actinomycetes as well as on the amoA gene of AOA and AOB was greatly reinforced."( Separate and joint eco-toxicological effects of sulfadimidine and copper on soil microbial biomasses and ammoxidation microorganisms abundances.
Ahmad, Z; Wang, J; Wang, L; Wei, Z; Xia, X; Zhang, W; Zhu, L, 2019
)
0.51
" A gene dose-response relationship was exhibited as intermediate acetylators catalyzed 4-aminobiphenyl N-acetylation both in vitro and in situ at rates arithmetically between rapid and slow acetylators."( N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes.
Doll, MA; Habil, MR; Hein, DW, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
ligandAny molecule or ion capable of binding to a central metal atom to form coordination complexes.
antibacterial drugA drug used to treat or prevent bacterial infections.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 2.5.1.15 (dihydropteroate synthase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.04470.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.00690.006038.004119,952.5996AID1159521
Fumarate hydrataseHomo sapiens (human)Potency14.12540.00308.794948.0869AID1347053
AR proteinHomo sapiens (human)Potency44.56350.000221.22318,912.5098AID588515; AID588516
thioredoxin glutathione reductaseSchistosoma mansoniPotency89.12510.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency69.35760.001022.650876.6163AID1224838; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency13.96280.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency62.94370.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.51700.000229.305416,493.5996AID743069; AID743075; AID743079
polyproteinZika virusPotency14.12540.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.33490.001024.504861.6448AID743215
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency8.687719.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency26.91840.000323.4451159.6830AID743065; AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency69.35760.000627.21521,122.0200AID743219
survival motor neuron protein isoform dHomo sapiens (human)Potency1.00000.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID750781Antimicrobial activity against Salmonella typhi ATCC 23564 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID94204Antibacterial activity against Klebsiella pneumoniae at a concentration of 40 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID750785Antimicrobial activity against Bacillus cereus MTCC 7350 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID649901Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649905Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID750788Antimicrobial activity against Bacillus cereus MTCC 7350 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID670244Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Synthesis and antimycobacterial activity of some phthalimide derivatives.
AID253052Antibacterial activity of compound against Escherichia coli at 10 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID253056Antibacterial activity of compound against Bacillus subtilis at 10 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID750777Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID649909Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649907Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649902Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID253057Antibacterial activity of compound against Bacillus subtilis at 20 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID649904Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID253058Antibacterial activity of compound against Bacillus subtilis at 40 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID750773Antimicrobial activity against Escherichia coli ATCC 35218 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID649903Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID750792Antimicrobial activity against Staphylococcus aureus ATCC 11632 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID649898Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID40929Antibacterial activity against Bacillus subtilis at a concentration of 160 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID750789Antimicrobial activity against Staphylococcus aureus ATCC 11632 after 24 hrs by broth micro serial dilution method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID280386Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
AID70303Antibacterial activity against Escherichia coli at a concentration of 20 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID253059Antibacterial activity of compound against Bacillus subtilis at 80 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID649900Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649908Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649899Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID70305Antibacterial activity against Escherichia coli at a concentration of 40 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID649896Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649892Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID94080Antibacterial activity against Klebsiella pneumoniae at a concentration of 120 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID750780Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID253054Antibacterial activity of compound against Escherichia coli at 40 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID750784Antimicrobial activity against Salmonella typhi ATCC 23564 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID64419Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.4;ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID94206Antibacterial activity against Klebsiella pneumoniae at a concentration of 80 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID40931Antibacterial activity against Bacillus subtilis at a concentration of 40 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID649895Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID94202Antibacterial activity against Klebsiella pneumoniae at a concentration of 160 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID40933Antibacterial activity against Bacillus subtilis at a concentration of 80 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID253055Antibacterial activity of compound against Escherichia coli at 80 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID750776Antimicrobial activity against Escherichia coli ATCC 35218 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method2013European journal of medicinal chemistry, Jun, Volume: 64Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID253053Antibacterial activity of compound against Escherichia coli at 20 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID25817PKa value was measured1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID70301Antibacterial activity against Escherichia coli at a concentration of 10 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID649897Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID40927Antibacterial activity against Bacillus subtilis at a concentration of 120 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID70307Antibacterial activity against Escherichia coli at a concentration of 80 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID649906Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID599143Lipophilicity, log P of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,479)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990793 (53.62)18.7374
1990's183 (12.37)18.2507
2000's135 (9.13)29.6817
2010's253 (17.11)24.3611
2020's115 (7.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.58 (24.57)
Research Supply Index7.42 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index83.89 (26.88)
Search Engine Supply Index2.36 (0.95)

This Compound (43.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials52 (3.21%)5.53%
Reviews23 (1.42%)6.00%
Case Studies20 (1.23%)4.05%
Observational0 (0.00%)0.25%
Other1,525 (94.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the PACE/PACENET BHL Clinical Program [NCT02463266]4,000 participants (Anticipated)Observational2014-03-31Enrolling by invitation
Study Protocol of the EMPOWER-SUSTAIN Project: A Pilot Randomised Controlled Trial of e-Health Intervention to Improve Patient Activation and Self-Management Behaviours Among Individuals With Metabolic Syndrome in Primary Care Setting [NCT04120779]232 participants (Anticipated)Interventional2021-03-01Not yet recruiting
Strengthening Person-centered Accessibility, Respect, and Quality of Maternal Health Services in India, Phase 2 [NCT04208841]1,971 participants (Actual)Interventional2018-05-14Completed
Comparison of Dry Needling and Sustained Pressure in Trigger Points of Lumbar Paraspinal Muscles [NCT04043741]50 participants (Actual)Interventional2019-03-01Completed
Clinical & Web-based Diet & Activity Counseling for Men [NCT00412633]442 participants (Actual)Interventional2004-02-29Completed
Evaluation of an mHealth Intervention to Improve Women's Access to Maternal Health Services in Rural Tanzania [NCT03161184]572 participants (Actual)Interventional2013-07-23Completed
Intervention Trial Designed to Promote Collegiality and Mutual Support at Work as a Way to Increase Meaning in Work and Reduce Burnout [NCT04466423]125 participants (Actual)Interventional2013-09-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]